The stock of Edwards Lifesciences Corp (NYSE: EW) has increased by 1.26 when compared to last closing price of 70.46. Despite this, the company has experienced a 1.02% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-22 that Health Care and Energy sectors outperform in 2025, with the Health Care Select Sector SPDR Fund ETF up 7% YTD, while Edwards Lifesciences lags. Despite a solid Q4 earnings beat, EW’s shares remain undervalued with a reduced P/E multiple of 33x, yielding a price target of $84. Key risks include slower TAVR growth in Japan and hospital demand uncertainties, but long-term sales growth targets remain optimistic.
Is It Worth Investing in Edwards Lifesciences Corp (NYSE: EW) Right Now?
Edwards Lifesciences Corp (NYSE: EW) has a price-to-earnings ratio of 29.94x that is above its average ratio. Additionally, the 36-month beta value for EW is 1.17. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 5 rating it as “overweight,” 18 rating it as “hold,” and 1 rating it as “sell.”
The public float for EW is 576.41M and currently, short sellers hold a 1.47% ratio of that float. The average trading volume of EW on March 25, 2025 was 4.46M shares.
EW’s Market Performance
EW’s stock has seen a 1.02% increase for the week, with a -2.66% drop in the past month and a -2.01% fall in the past quarter. The volatility ratio for the week is 1.91%, and the volatility levels for the past 30 days are at 2.47% for Edwards Lifesciences Corp The simple moving average for the last 20 days is 1.10% for EW stock, with a simple moving average of -2.12% for the last 200 days.
Analysts’ Opinion of EW
Many brokerage firms have already submitted their reports for EW stocks, with Stifel repeating the rating for EW by listing it as a “Buy.” The predicted price for EW in the upcoming period, according to Stifel is $90 based on the research report published on January 30, 2025 of the current year 2025.
Wolfe Research, on the other hand, stated in their research note that they expect to see EW reach a price target of $60. The rating they have provided for EW stocks is “Underperform” according to the report published on January 16th, 2025.
EW Trading at -0.06% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.77% of loss for the given period.
Volatility was left at 2.47%, however, over the last 30 days, the volatility rate increased by 1.91%, as shares sank -1.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.78% lower at present.
During the last 5 trading sessions, EW rose by +1.02%, which changed the moving average for the period of 200-days by -18.37% in comparison to the 20-day moving average, which settled at $70.57. In addition, Edwards Lifesciences Corp saw -3.62% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EW starting from BOBO DONALD E JR, who sale 9,500 shares at the price of $67.96 back on Mar 13 ’25. After this action, BOBO DONALD E JR now owns 46,936 shares of Edwards Lifesciences Corp, valued at $645,624 using the latest closing price.
Zovighian Bernard J, the CEO of Edwards Lifesciences Corp, sale 6,164 shares at $69.51 during a trade that took place back on Mar 10 ’25, which means that Zovighian Bernard J is holding 59,083 shares at $428,448 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- 0.26 for the present operating margin
- 0.78 for the gross margin
The net margin for Edwards Lifesciences Corp stands at 0.73. The total capital return value is set at 0.13. Equity return is now at value 17.17, with 12.75 for asset returns.
Based on Edwards Lifesciences Corp (EW), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 0.77.
Currently, EBITDA for the company is 1.72 billion with net debt to EBITDA at -1.29. When we switch over and look at the enterprise to sales, we see a ratio of 6.92. The receivables turnover for the company is 7.87for trailing twelve months and the total asset turnover is 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.18.
Conclusion
In conclusion, Edwards Lifesciences Corp (EW) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
